(Q35068040)

6 August 2017

1 reference

title

Current management of portal hypertension. (English)

1 reference

6 August 2017

1 reference

1

Jaime Bosch

1 reference

6 August 2017

Juan G Abraldes

2

1 reference

6 August 2017

Roberto Groszmann

series ordinal

3

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

published in

Journal of Hepatology

1 reference

6 August 2017

volume

38 Suppl 1

1 reference

6 August 2017

page(s)

S54-68

1 reference

Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection?

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Pharmacological treatment of portal hypertension: an evidence-based approach

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Natural history of cirrhotic patients with small esophageal varices: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Natural history of portal hypertension in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Hemodynamic factors involved in the development and rupture of esophageal varices: a pathophysiologic approach to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Portal pressure, presence of gastroesophageal varices and variceal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Improving prognosis following a first variceal haemorrhage over four decades

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

A predictive model for failure to control bleeding during acute variceal haemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Prognostic value of early measurements of portal pressure in acute variceal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Renal failure after upper gastrointestinal bleeding in cirrhosis: Incidence, clinical course, predictive factors, and short-term prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Portal hypertension and variceal bleeding: an AASLD single topic symposium

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Diagnosing portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Clinical events after transjugular intrahepatic portosystemic shunt: Correlation with hemodynamic findings

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Effect of vasodilators on hepatic microcirculation in cirrhosis: a study in the isolated perfused rat liver.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Propranolol--a medical treatment for portal hypertension?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multic

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Non-selective beta-blockers in the prevention of first variceal bleeding. Is there any definite alternative?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

"A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Endoscopic treatments for portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Endoscopic variceal banding vs. pharmacological therapy for the prevention of recurrent variceal hemorrhage: what makes the difference?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Transjugular intrahepatic portosystemic shunt

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Why portal hypertensive varices bleed and bleed: a hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

The role of portal pressure in the severity of bleeding in portal hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Management of variceal haemorrhage in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Early administration of vapreotide for variceal bleeding in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Octreotide for acute esophageal variceal bleeding: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Somatostatin and analogues in portal hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Somatostatin alone or combined with emergency sclerotherapy in the treatment of acute esophageal variceal bleeding: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Emergency sclerotherapy versus medical interventions for bleeding oesophageal varices in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Salvage transjugular intrahepatic portosystemic shunt: is it really life-saving?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Salvage therapies for refractory variceal hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

(--)-Timolol is a more potent antagonist of the positive inotropic effects of (--)-adrenaline than of those of (--)-noradrenaline in human atrium

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Effect of selective blockade of beta 2-adrenergic receptors on portal and systemic hemodynamics in a portal hypertensive rat model

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Comparison of the effects of a cardioselective and a nonselective beta-blocker on portal hypertension in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Effects of Propranolol on Azygos Venous Blood Flow and Hepatic and Systemic Hemodynamics in Cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Short-term effects of propranolol on portal venous pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

The portal pressure response to beta-blockade is greater in cirrhotic patients without varices than in those with varices

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Low-dose midazolam sedation: an option for patients undergoing serial hepatic venous pressure measurements.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleed: preliminary report of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Blood in the gastric lumen increases splanchnic blood flow and portal pressure in portal-hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Efficacy of balloon tamponade in treatment of bleeding gastric and esophageal varices. Results in 151 consecutive episodes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Gastric varices and portal hypertensive gastropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Endoscopic treatment of bleeding gastric varices by N-butyl-2-cyanoacrylate (Histoacryl) injection: long-term efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

EUS-guided injection of cyanoacrylate for bleeding gastric varices

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Bucrylate treatment of bleeding gastric varices: 12 years' experience

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

An open pilot study of the effects of a human fibrin glue for endoscopic treatment of patients with acute bleeding from gastric varices

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Endoscopic use of human thrombin in bleeding gastric varices

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

"Salvage" transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. The New Italian Endoscopic Club for the study and treatment of esophageal varices (NIEC)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Somatostatin for acute severe bleeding from portal hypertensive gastropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

The effects of transjugular intrahepatic portosystemic shunt on portal hypertensive gastropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Portal Hypertensive gastropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Transjugular intrahepatic portosystemic shunt vs. small-diameter prosthetic H-graft portacaval shunt: extended follow-up of an expanded randomized prospective trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Incidence of shunt occlusion or stenosis following transjugular intrahepatic portosystemic shunt placement

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Preliminary results of a new expanded-polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Acute propranolol administration effectively decreases portal pressure in patients with TIPS dysfunction. Transjugular intrahepatic portosystemic shunt

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in patients with TIPS.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Continuous prazosin administration in cirrhotic patients: Effects on portal hemodynamics and on liver and renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Chronic blockade of endothelin receptors in cirrhotic rats: Hepatic and hemodynamic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Gene transfer of recombinant endothelial nitric oxide synthase to liver in vivo and in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

NO synthase in the liver: prospects of in vivo gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Complications of cirrhosis. I. Portal hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

The effect of nitric oxide synthase inhibition on portal pressure and azygos blood flow in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900430-0

7 January 2021

10.1016/S0168-8278(02)00430-0

Identifiers

DOI

1 reference

6 August 2017

1 reference